The United Arab Emirates has officially granted conditional approval for the use of AstraZeneca’s medication, Ultomiris (ravulizumab), to treat adults suffering from primary immunoglobulin A nephropathy (IgAN). This condition is an immune-mediated disorder where immune proteins accumulate in kidney tissue, triggering inflammation that can severely impair renal function over time. By targeting the reduction of proteinuria—excess protein in the urine—this new treatment option offers a critical intervention for patients at a high risk of disease progression.

This regulatory milestone aligns with the UAE's broader "We the UAE 2031" vision, which emphasizes innovation and global competitiveness within the pharmaceutical and healthcare sectors. The Emirates Drug Establishment (EDE) noted that this decision reflects their commitment to creating a proactive and efficient regulatory framework. Health officials continue to underscore that while this new therapy is a significant step forward, successful patient outcomes remain heavily dependent on early diagnosis, consistent monitoring of kidney health, and strict adherence to specialist-led treatment plans.